Utility of MLAST in an efficacy trial using Kras/Lkb1 GEM model.
figureposted on 2021-06-17, 17:30 authored by Mary Katherine Montgomery, John David, Haikuo Zhang, Sripad Ram, Shibing Deng, Vidya Premkumar, Lisa Manzuk, Ziyue Karen Jiang, Anand Giddabasappa
(A) Manual scores assigned to scans from vehicle control (blue) and drug treatment (pink) groups before (baseline) and 3 weeks post-treatment regimen. (B) MLAST scores from vehicle (blue) and drug treatment (pink) groups before and post-treatment regimen. (C) Representative images from vehicle control and drug treated groups before and post-treatment. Images show profound progression of tumor in vehicle control group, but not in drug treated group. (n = 10/group; +/- SEM; ** = p-value < 0.0001).